Lp(a) as a Risk Factor for Peripheral Artery Disease: Context Is Everything

Area of Science:

• Cardiovascular Medicine
• Lipidology
• Vascular Biology

Background:

• Elevated lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular diseases.
• Lp(a) has proatherosclerotic, proinflammatory, procalcific, and prothrombotic effects, but precise pathogenic mechanisms remain unclear.
• The distinct roles of Lp(a) in different vascular sites, particularly in peripheral artery disease (PAD) above and below the knee, are not fully understood.

Purpose of the Study:

• To explore the precise pathogenic mechanisms of Lp(a) in atherosclerotic cardiovascular diseases.
• To investigate the differential contribution of Lp(a) to PAD in various vascular locations.
• To highlight the unmet clinical need for Lp(a)-lowering therapies in PAD management.

Main Methods:

• Review of existing literature on Lp(a) and its association with atherosclerotic cardiovascular diseases.
• Analysis of the specific pathological features of PAD, including plaque rupture and medial calcification.
• Examination of clinical outcomes associated with elevated Lp(a) in PAD patients.

Main Results:

• Elevated Lp(a) is strongly associated with a spectrum of PAD outcomes, including incident claudication, disease progression, revascularization, and major adverse leg events.
• Lp(a) poses a risk for PAD comparable to its risk for coronary artery disease.
• The specific mechanisms by which Lp(a) contributes to PAD, especially the differences between above-knee and below-knee disease, require further elucidation.

Conclusions:

• Elevated Lp(a) is a potent and independent risk factor for peripheral artery disease (PAD).
• Targeting Lp(a) represents a critical unmet need for both the prevention and treatment of PAD.
• Clinical trials assessing RNA-directed Lp(a)-lowering therapies for PAD events are the essential next step.